Breaking News

Monday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Initiation
Fly Intel: Top five analyst initiations » 10:11
08/03/20
08/03
10:11
08/03/20
10:11
MIRM

Mirum Pharmaceuticals

$23.21 /

+1.22 (+5.55%)

, ORIC

ORIC Pharmaceuticals

$20.45 /

+0.4699 (+2.35%)

, STOR

Store Capital

$23.25 /

-0.445 (-1.88%)

, GERN

Geron

$1.66 /

+0.065 (+4.08%)

, PRPL

Purple Innovation

$25.25 /

+0.875 (+3.59%)

Catch up on today's…

Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Mirum Pharmaceuticals (MIRM) initiated with a Buy at H.C. Wainwright. 2. ORIC Pharmaceuticals (ORIC) initiated with a Buy at H.C. Wainwright. 3. Store Capital (STOR) initiated with an Outperform at Evercore ISI. 4. Geron (GERN) initiated with a Buy at Stifel. 5. Purple Innovation (PRPL) initiated with a Buy at Craig-Hallum. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

ShowHide Related Items >><<
STOR Store Capital
$23.25 /

-0.445 (-1.88%)

PRPL Purple Innovation
$25.25 /

+0.875 (+3.59%)

ORIC ORIC Pharmaceuticals
$20.45 /

+0.4699 (+2.35%)

MIRM Mirum Pharmaceuticals
$23.21 /

+1.22 (+5.55%)

GERN Geron
$1.66 /

+0.065 (+4.08%)

MIRM Mirum Pharmaceuticals
$23.21 /

+1.22 (+5.55%)

08/03/20 H.C. Wainwright
Mirum Pharmaceuticals initiated with a Buy at H.C. Wainwright
07/30/20 Piper Sandler
Mirum Pharmaceuticals initiated with an Overweight at Piper Sandler
06/24/20 Baird
Mirum Pharmaceuticals initiated with an Outperform at Baird
03/23/20 Citi
Sarepta, DBV among Citi's SMid Biotech picks amid coronavirus outbreak
ORIC ORIC Pharmaceuticals
$20.45 /

+0.4699 (+2.35%)

08/03/20 H.C. Wainwright
ORIC Pharmaceuticals initiated with a Buy at H.C. Wainwright
06/11/20 Oppenheimer
Oppenheimer starts ORIC Pharmaceuticals at Outperform with $48 target
06/11/20 Oppenheimer
ORIC Pharmaceuticals initiated with a Perform at Oppenheimer
05/19/20
Fly Intel: Top five analyst initiations
STOR Store Capital
$23.25 /

-0.445 (-1.88%)

08/03/20 Evercore ISI
Store Capital initiated with an Outperform at Evercore ISI
06/29/20 Jefferies
Store Capital initiated with a Buy at Jefferies
06/18/20 Wells Fargo
Store Capital price target raised to $24 from $19 at Wells Fargo
06/16/20 Mizuho
Store Capital price target raised to $24 from $17 at Mizuho
GERN Geron
$1.66 /

+0.065 (+4.08%)

08/03/20 Stifel
Geron initiated with a Buy at Stifel
11/19/19 B. Riley FBR
B. Riley FBR resumes Geron with Buy rating, $4 price target
11/19/19 B. Riley FBR
Geron resumed with a Buy at B. Riley FBR
09/03/19 H.C. Wainwright
Geron initiated with a Buy at H.C. Wainwright
PRPL Purple Innovation
$25.25 /

+0.875 (+3.59%)

08/03/20 Craig-Hallum
Purple Innovation initiated with a Buy at Craig-Hallum
07/28/20 Oppenheimer
Purple Innovation price target raised to $25 from $19 at Oppenheimer
07/16/20 Wedbush
Sleep Number price target raised to $52 from $30 at Wedbush
06/16/20
Fly Intel: Top five analyst initiations
STOR Store Capital
$23.25 /

-0.445 (-1.88%)

PRPL Purple Innovation
$25.25 /

+0.875 (+3.59%)

MIRM Mirum Pharmaceuticals
$23.21 /

+1.22 (+5.55%)

GERN Geron
$1.66 /

+0.065 (+4.08%)

  • 22
    May
  • 15
    May
  • 24
    Apr
  • 09
    Jan
  • 15
    Nov
STOR Store Capital
$23.25 /

-0.445 (-1.88%)

PRPL Purple Innovation
$25.25 /

+0.875 (+3.59%)

ORIC ORIC Pharmaceuticals
$20.45 /

+0.4699 (+2.35%)

GERN Geron
$1.66 /

+0.065 (+4.08%)

STOR Store Capital
$23.25 /

-0.445 (-1.88%)

PRPL Purple Innovation
$25.25 /

+0.875 (+3.59%)

GERN Geron
$1.66 /

+0.065 (+4.08%)

Initiation
Mirum Pharmaceuticals initiated with a Buy at H.C. Wainwright » 06:06
08/03/20
08/03
06:06
08/03/20
06:06
MIRM

Mirum Pharmaceuticals

$21.99 /

+0.79 (+3.73%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Ed Arce initiated coverage of Mirum Pharmaceuticals with a Buy rating and $52 price target. The analyst expects one New Drug Application filing with two indications, Allagille syndrome and progressive familial intrahepatic cholestasis to be accepted in Q1 of 2021, followed by a six month Priority Review leading to U.S. approval and launch in second half of 2021. He sees this as a "substantial potential catalyst" for the shares.

ShowHide Related Items >><<
MIRM Mirum Pharmaceuticals
$21.99 /

+0.79 (+3.73%)

MIRM Mirum Pharmaceuticals
$21.99 /

+0.79 (+3.73%)

07/30/20 Piper Sandler
Mirum Pharmaceuticals initiated with an Overweight at Piper Sandler
06/24/20 Baird
Mirum Pharmaceuticals initiated with an Outperform at Baird
03/23/20 Citi
Sarepta, DBV among Citi's SMid Biotech picks amid coronavirus outbreak
12/17/19 Citi
Mirum Pharmaceuticals price target raised to $30 from $21 at Citi
MIRM Mirum Pharmaceuticals
$21.99 /

+0.79 (+3.73%)

  • 09
    Jan
Thursday
Initiation
Mirum Pharmaceuticals initiated with an Overweight at Piper Sandler » 16:23
07/30/20
07/30
16:23
07/30/20
16:23
MIRM

Mirum Pharmaceuticals

$21.50 /

+1.3 (+6.44%)

Piper Sandler analyst…

Piper Sandler analyst Yasmeen Rahimi initiated coverage of Mirum Pharmaceuticals with an Overweight rating and $77 price target. The analyst sees 280% upside given the "key imminent event" of a New Drug Application submission for Mirum's IBAT inhibitor maralixibat in the pediatric cholestasis disease Alagille syndrome and its planned MAA submission for maralixibat in PFIC2 in Europe. Rahimi's "conviction is high" on these further maralixibat indications.

ShowHide Related Items >><<
MIRM Mirum Pharmaceuticals
$21.50 /

+1.3 (+6.44%)

MIRM Mirum Pharmaceuticals
$21.50 /

+1.3 (+6.44%)

06/24/20 Baird
Mirum Pharmaceuticals initiated with an Outperform at Baird
03/23/20 Citi
Sarepta, DBV among Citi's SMid Biotech picks amid coronavirus outbreak
12/17/19 Citi
Mirum Pharmaceuticals price target raised to $30 from $21 at Citi
12/16/19 Roth Capital
Mirum update shortens development timeframe by two years, says Roth Capital
MIRM Mirum Pharmaceuticals
$21.50 /

+1.3 (+6.44%)

  • 09
    Jan
Over a month ago
Conference/Events
Mirum Pharmaceuticals management to meet virtually with Roth Capital » 04:55
07/02/20
07/02
04:55
07/02/20
04:55
MIRM

Mirum Pharmaceuticals

$20.02 /

+0.59 (+3.04%)

Virtual Meeting to be…

Virtual Meeting to be held on July 2 hosted by Roth Capital.

ShowHide Related Items >><<
MIRM Mirum Pharmaceuticals
$20.02 /

+0.59 (+3.04%)

MIRM Mirum Pharmaceuticals
$20.02 /

+0.59 (+3.04%)

06/24/20 Baird
Mirum Pharmaceuticals initiated with an Outperform at Baird
03/23/20 Citi
Sarepta, DBV among Citi's SMid Biotech picks amid coronavirus outbreak
12/17/19 Citi
Mirum Pharmaceuticals price target raised to $30 from $21 at Citi
12/16/19 Roth Capital
Mirum update shortens development timeframe by two years, says Roth Capital
MIRM Mirum Pharmaceuticals
$20.02 /

+0.59 (+3.04%)

  • 09
    Jan
  • 18
    Jul
Conference/Events
Mirum Pharmaceuticals management to meet virtually with Roth Capital » 09:26
06/26/20
06/26
09:26
06/26/20
09:26
MIRM

Mirum Pharmaceuticals

$20.80 /

+0.27 (+1.32%)

Virtual Meeting to be…

Virtual Meeting to be held on July 2 hosted by Roth Capital.

ShowHide Related Items >><<
MIRM Mirum Pharmaceuticals
$20.80 /

+0.27 (+1.32%)

MIRM Mirum Pharmaceuticals
$20.80 /

+0.27 (+1.32%)

06/24/20 Baird
Mirum Pharmaceuticals initiated with an Outperform at Baird
03/23/20 Citi
Sarepta, DBV among Citi's SMid Biotech picks amid coronavirus outbreak
12/17/19 Citi
Mirum Pharmaceuticals price target raised to $30 from $21 at Citi
12/16/19 Roth Capital
Mirum update shortens development timeframe by two years, says Roth Capital
MIRM Mirum Pharmaceuticals
$20.80 /

+0.27 (+1.32%)

  • 09
    Jan
  • 18
    Jul
Conference/Events
Mirum Pharmaceuticals management to meet virtually with Roth Capital » 04:55
06/26/20
06/26
04:55
06/26/20
04:55
MIRM

Mirum Pharmaceuticals

$20.80 /

+0.27 (+1.32%)

Virtual Meeting to be…

Virtual Meeting to be held on June 26 hosted by Roth Capital.

ShowHide Related Items >><<
MIRM Mirum Pharmaceuticals
$20.80 /

+0.27 (+1.32%)

MIRM Mirum Pharmaceuticals
$20.80 /

+0.27 (+1.32%)

06/24/20 Baird
Mirum Pharmaceuticals initiated with an Outperform at Baird
03/23/20 Citi
Sarepta, DBV among Citi's SMid Biotech picks amid coronavirus outbreak
12/17/19 Citi
Mirum Pharmaceuticals price target raised to $30 from $21 at Citi
12/16/19 Roth Capital
Mirum update shortens development timeframe by two years, says Roth Capital
MIRM Mirum Pharmaceuticals
$20.80 /

+0.27 (+1.32%)

  • 09
    Jan
  • 18
    Jul
Initiation
Mirum Pharmaceuticals initiated with an Outperform at Baird » 16:11
06/24/20
06/24
16:11
06/24/20
16:11
MIRM

Mirum Pharmaceuticals

$20.24 /

-0.74 (-3.53%)

Baird analyst Brian…

Baird analyst Brian Skorney initiated coverage of Mirum Pharmaceuticals with an Outperform rating and $30 price target. The company's maralixibat looks poised to become first approved treatment for Alagille syndrome following a positive pre-NDA meeting with the FDA in late-2019, Skorney said. He believes it is "very likely" that the company's new drug application is approved in 2021, providing entry into a market opportunity that exceeds $500M, the analyst added.

ShowHide Related Items >><<
MIRM Mirum Pharmaceuticals
$20.24 /

-0.74 (-3.53%)

MIRM Mirum Pharmaceuticals
$20.24 /

-0.74 (-3.53%)

03/23/20 Citi
Sarepta, DBV among Citi's SMid Biotech picks amid coronavirus outbreak
12/17/19 Citi
Mirum Pharmaceuticals price target raised to $30 from $21 at Citi
12/16/19 Roth Capital
Mirum update shortens development timeframe by two years, says Roth Capital
08/12/19
Fly Intel: Top five analyst initiations
MIRM Mirum Pharmaceuticals
$20.24 /

-0.74 (-3.53%)

Conference/Events
Mirum Pharmaceuticals management to meet virtually with Roth Capital » 04:55
06/23/20
06/23
04:55
06/23/20
04:55
MIRM

Mirum Pharmaceuticals

$20.00 /

+0.38 (+1.94%)

Virtual Meeting to be…

Virtual Meeting to be held June 23 hosted by Roth Capital.

ShowHide Related Items >><<
MIRM Mirum Pharmaceuticals
$20.00 /

+0.38 (+1.94%)

MIRM Mirum Pharmaceuticals
$20.00 /

+0.38 (+1.94%)

03/23/20 Citi
Sarepta, DBV among Citi's SMid Biotech picks amid coronavirus outbreak
12/17/19 Citi
Mirum Pharmaceuticals price target raised to $30 from $21 at Citi
12/16/19 Roth Capital
Mirum update shortens development timeframe by two years, says Roth Capital
08/12/19
Fly Intel: Top five analyst initiations
MIRM Mirum Pharmaceuticals
$20.00 /

+0.38 (+1.94%)

Conference/Events
Mirum Pharmaceuticals management to meet virtually with Roth Capital » 08:28
06/19/20
06/19
08:28
06/19/20
08:28
MIRM

Mirum Pharmaceuticals

$18.18 /

-0.78 (-4.11%)

Virtual Meeting to be…

Virtual Meeting to be held on June 26 hosted by Roth Capital.

ShowHide Related Items >><<
MIRM Mirum Pharmaceuticals
$18.18 /

-0.78 (-4.11%)

MIRM Mirum Pharmaceuticals
$18.18 /

-0.78 (-4.11%)

03/23/20 Citi
Sarepta, DBV among Citi's SMid Biotech picks amid coronavirus outbreak
12/17/19 Citi
Mirum Pharmaceuticals price target raised to $30 from $21 at Citi
12/16/19 Roth Capital
Mirum update shortens development timeframe by two years, says Roth Capital
08/12/19
Fly Intel: Top five analyst initiations
MIRM Mirum Pharmaceuticals
$18.18 /

-0.78 (-4.11%)

Conference/Events
Mirum Pharmaceuticals management to meet virtually with Roth Capital » 08:27
06/19/20
06/19
08:27
06/19/20
08:27
MIRM

Mirum Pharmaceuticals

$18.18 /

-0.78 (-4.11%)

Virtual Meeting to be…

Virtual Meeting to be held June 23 hosted by Roth Capital.

ShowHide Related Items >><<
MIRM Mirum Pharmaceuticals
$18.18 /

-0.78 (-4.11%)

MIRM Mirum Pharmaceuticals
$18.18 /

-0.78 (-4.11%)

03/23/20 Citi
Sarepta, DBV among Citi's SMid Biotech picks amid coronavirus outbreak
12/17/19 Citi
Mirum Pharmaceuticals price target raised to $30 from $21 at Citi
12/16/19 Roth Capital
Mirum update shortens development timeframe by two years, says Roth Capital
08/12/19
Fly Intel: Top five analyst initiations
MIRM Mirum Pharmaceuticals
$18.18 /

-0.78 (-4.11%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.